ORLANDO — In this video from the American Academy of Ophthalmology meeting, Arshad M. Khanani, MD, MA, FASRS, discusses developments in the treatment of neovascular age-related macular degeneration.
Khanani delved into tyrosine kinase inhibitors, including the SOL-1 and SOL-R trials evaluating OTX-TKI (axitinib implant, Ocular Therapeutix) in neovascular AMD and the LUCIA and LUGANO studies of vorolanib (EyePoint Pharmaceuticals), which is designed to be delivered every 6 months to treat neovascular AMD.
Khanani also touched on gene therapy programs in development: ABBV-RGX-314 (AbbVie,